Euronext Paris

TME Pharma N.V.

HealthcareLEI 724500EPNADXWZ58U595Filings at the AFM Nederlands

At a glance

Most recent filing on October 7, 2026 — a grant by Izeboud C.A. on Sep 26, 2026.

Over the past 12 months: 0 open-market purchases and 4 open-market sales.

We hold 32 visible filings, going back to July 17, 2019.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 32 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings for this company, out of 32. Reading the whole list, and the full filer page behind every line, is part of the subscription. So are the insider score for this company, the price beside each line, the price history with every buy marked on it, any moments when several insiders bought within ninety days, and following this company. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Izeboud C.A. Member of the Supervisory Board
188,377 sharesGrant
TradedSep 26, 2026FiledOct 7, 2026
Schalop L. Member of the Supervisory Board
188,377 sharesGrant
TradedSep 29, 2026FiledOct 2, 2026
Petitbon M. Chairperson of the Supervisory Board
188,377 sharesGrant
TradedSep 29, 2026FiledOct 2, 2026
Eulberg D. Managing Director / Chief Operating Officer
188,377 sharesGrant
TradedSep 29, 2026FiledOct 2, 2026
Ouden, van den D.M. Managing Director / Chief Executive Officer
€170,000Open-market sale
TradedAug 26, 2026FiledAug 28, 2026

The insider score is a rank of the most recent scored buy, not a forecast. How it is calculated is in the methodology. Source: the Dutch AFM register (MAR art. 19).